TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12242580
Drug: Pramipexole 0.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.27 mg
Study: 10224181
Drug: Surfactant lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant lavage with 15 mL/kg of diluted surfactant solution (Survanta) at a phospholipid concentration of 5 mg/mL administered in 2-mL aliquots
Study: 28181920
Drug: Standard-care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care group (physical therapy as ordered by the primary care team)
Study: 23714773
Drug: Atorvastatin (80‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80‐mg loading dose given a mean of 1.5 hours before percutaneous coronary intervention)
Study: 22120855
Drug: Eperisone 150
Normalized name: acetaminophen / phenyltoloxamine citrate Oral Tablet [Perisine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eperisone 150 mg/day in three divided doses
Study: 10672633
Drug: Alcohol (0.26-0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.26-0.28 g.kg-1)
Study: 22986437
Drug: Linaclotide 290
Normalized name: LINACLOTIDE 290MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linaclotide 290 μg once daily
Study: 3367257
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg melatonin
Study: 19086332
Drug: Alosetron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron treatment for 3 weeks
Study: 28343553
Drug: Amitriptyline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline plus ALA (600 mg) and n-3 PUFAs (docosahexaenoic acid 250 mg and eicosapentaenoic acid 16.67 mg)
Study: 27032639
Drug: Montelukast (add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (add-on therapy)
Study: 27032639
Drug: Standard steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard steroid treatment only (LDS group)
Study: 17873192
Drug: Daily routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily routine chest radiographs (CXRs)
Study: 17873192
Drug: Abandoning daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abandoning daily routine CXRs
Study: 9812772
Drug: Clonidine 75
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 75 micrograms + Sumatriptan 3 mg
Study: 7702795
Drug: Intravenous E-3174
Normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous E-3174 (20 mg infused over 4 h)
Study: 7702795
Drug: Intravenous E-3174
Normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous E-3174
Study: 30422443
Drug: Endobronchial photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial photodynamic therapy based on fluorescent diagnostics of photosensibilizator accumulation.
Study: 30422443
Drug: Standard method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard method of photodynamic therapy.
Study: 25499939
Drug: Xuezhikang 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang 1200 mg daily
Study: 25499939
Drug: Xuezhikang 2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang 2400 mg daily
Study: 2317014
Drug: 4-AP (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-AP (10 to 25 mg)
Study: 2317014
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose capsules)
Study: 396053
Drug: Praziquantel (1x20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (1x20, 2x20, or 3x20 mg/kg)
Study: 396053
Drug: Praziquantel (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (three oral doses of 20 mg/kg at 4-hour intervals)
Study: 396053
Drug: Praziquantel (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (single oral dose of 50 mg/kg)
Study: 396053
Drug: Praziquantel (treatment)
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel (treatment)
Study: 31495374
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment or treatment without medications
Study: 28606657
Drug: FGF‐2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGF‐2 plus Gelfoam patch
Study: 28606657
Drug: Gelfoam patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelfoam patch alone
Study: 16855451
Drug: Sertraline (SERT)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SERT)
Study: 22003157
Drug: Agility and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agility and perturbation training with standard exercise therapy
Study: 19847724
Drug: Pre-treatment counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment counselling
Study: 19847724
Drug: No pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-treatment counselling (control group)
Study: 15961713
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg/100 mL/d for 3 days)
Study: 8565025
Drug: Clindamycin hydrochloride
Normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin hydrochloride 150 mg QID for 10 days
Study: 8565025
Drug: Clindamycin hydrochloride
Normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin hydrochloride 300 mg BID plus placebo BID for 10 days
Study: 1726893
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy for osteosarcoma (4 or 9 weeks) with high doses of methotrexate, vincristine, and citrovorum factor rescue or BCD (bleomycin, cytoxan, actinomycin D) and CDDP (cisplatin).
Study: 1726893
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy continued for up to 2 years.
Study: 1726893
Drug: Radiotherapy for
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy for primary tumor with doses adjusted to tumor response (30-50 Gy or 50 Gy).
Study: 7034472
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside infusion during 24 hours, followed by six times a day 5 mg isosorbide dinitrate for seven days
Study: 11360851
Drug: Glucose 5%
Normalized name: Glucose 5% Nursette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 5% infusion
Study: 28708285
Drug: Green light
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green light (G-group)
Study: 23317527
Drug: Ciprofloxacin (CPFX)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (CPFX) 300 mg every 12h
Study: 19297117
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) intervention
Study: 17115380
Drug: Sumanirole 1
Normalized name: Sumanirole
DrugBank: Sumanirole (DB06477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumanirole 1 to 48 mg/day
Study: 17115380
Drug: Ropinirole 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole 0.75 to 24 mg/day
Study: 16030435
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g alcohol per day for 8 weeks
Study: 16030435
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g alcohol per day for 8 weeks
Study: 16030435
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g alcohol (control group)
Study: 7535952
Drug: Accelerated hyperfractionation
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionation with or without chemotherapy
Study: 7535952
Drug: Reirradiation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reirradiation with concomitant chemotherapy
Study: 1681960
Drug: Aspirin or
Normalized name: aspirin Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin or non-aspirin NSAIDs
Study: 1681960
Drug: Anti-secretory drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-secretory drugs and prostaglandins
Study: 7008819
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 3 ml with no glucose
Study: 7008819
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 3 ml with 5% glucose
Study: 7008819
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 3 ml with 8% glucose
Study: 31996053
Drug: Medicated chewing
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicated chewing gum (MCG) with taste-masked LCZ (drug/Kleptose complex 1:3 molar ratio)
Study: 24759933
Drug: Conventional tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablets
Study: 30779597
Drug: Hourly resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly resistance exercise breaks (REX)
Study: 28114769
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus common factors feedback (TAU + CFF)
Study: 23941811
Drug: Case-formulation driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case-formulation driven CBT
Study: 21612965
Drug: Ultrasound-guided injection
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided injection of steroid (betamethasone 7 mg)
Study: 21612965
Drug: Standard subacromial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard subacromial infiltration of 7 mg of betamethasone
Study: 19484679
Drug: Itraconazole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (50 mg/day)
Study: 19484679
Drug: Placebo (ambroxol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ambroxol hydrochloride 45 mg/day)
Study: 15513279
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g creatine monohydrate in solution
Study: 15513279
Drug: Creatine Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine Serum (5 ml)
Study: 11599461
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) administered in vivo
Study: 11599461
Drug: No Growth
Normalized name: Mechano growth factor
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No Growth Hormone (no GH)
Study: 2532790
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin (50 units/kg body weight intravenously immediately after antivenom followed by a continuous infusion of 10 units/kg/hr in isotonic saline for 24 hours)
Study: 27919979
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day (arm A)
Study: 27919979
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day + Docetaxel 75 mg/m2 (arm B)
Study: 7670096
Drug: rhuGM‐CSF 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuGM‐CSF 5.0 micrograms/kg twice per day
Study: 2208436
Drug: Replenishing zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replenishing zinc (RZ) group treated by 0.2% zinc sulphate syrup for 3 months
Study: 7429005
Drug: Erythromycin 2
Normalized name: erythromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 2 x 1 g/day for 48 hours, infused over 30 or 60 minutes at 12-hour intervals
Study: 27121539
Drug: 4-week extended-release
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week extended-release naltrexone (XR-NTX)
Study: 20953684
Drug: rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 5 mg + fenofibric acid 135 mg
Study: 20953684
Drug: fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibric acid 135 mg
Study: 16102948
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 IU weekly (q.w.)
Study: 1482222
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine treatment (Catapres‐TTS No. 2)
Study: 29663044
Drug: 5-day PCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day PCT algorithm with predefined cutoff values for the initiation or stoppage of antibiotics (PCT group)
Study: 26469139
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (doxorubicin-cyclophosphamide followed by weekly paclitaxel) in arm A
Study: 26469139
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab (doxorubicin-cyclophosphamide followed by weekly paclitaxel plus trastuzumab) in arm C
Study: 11001085
Drug: MPA 60
Normalized name: MPA
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA 60 mg daily for 14 days
Study: 8803515
Drug: Moexipril 7.5
Normalized name: moexipril 7.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 7.5 mg o.d.
Study: 8803515
Drug: Moexipril 15
Normalized name: moexipril 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril 15 mg o.d.
Study: 9489083
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 mg o.d.
Study: 1730810
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 and vaginal P (group I, n = 11)
Study: 30714750
Drug: Nondirective therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondirective therapy (ND)
Study: 31944806
Drug: RNT-focused acceptance
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNT-focused acceptance and commitment therapy (ACT)
Study: 30639922
Drug: PATCH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATCH (100 mcg transdermal 17β-estradiol with cyclic progesterone)
Study: 30639922
Drug: PILL (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PILL (30 mcg ethinyl estradiol + 0.15 mg desogestrel)
Study: 30639922
Drug: PATCH
Normalized name: Patch
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATCH
Study: 30639922
Drug: PILL
Normalized name: PILL
Approvals — FDA: no, EMA: no, PMDA: no
Description: PILL
Study: 12514902
Drug: Antisperm antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisperm antibodies
Study: 22517315
Drug: Scopolamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.4 mg)
Study: 23568575
Drug: Scopolamine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.6 mg)
Study: 9725548
Drug: Scopolamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.8 mg)
Study: 7976643
Drug: Continuous monitoring
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous monitoring of jugular venous oxygen saturation and BTT/TMT during cerebral hypothermia treatment
Study: 2647187
Drug: rh GM‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh GM‐CSF (recombinant human granulocyte/macrophage colony stimulating factor) administered by continuous infusion for 3‐21 days at doses of 100‐400 micrograms/m2/day
Study: 23706644
Drug: TEA lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEA lidocaine (0.15 mL/kg of 1.35% lidocaine)
Study: 21875912
Drug: Sildenafil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil treatment for 12 weeks in HF+EOV subjects
Study: 11765304
Drug: Nonnicotine pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonnicotine pharmacotherapy (bupropion, nortriptyline, moclobemide)
Study: 31863284
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg alone (Period 1)
Study: 31863284
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg with rifampin 600 mg/day (Period 2)
Study: 28228114
Drug: Sildenafil 1
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 1 mg TID
Study: 24095005
Drug: Tramadol HCl
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol HCl 50 mg and adrenaline 0.0225 mg diluted to 1.8 mL by distilled water (Group A)
Study: 24095005
Drug: Tramadol HCl
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol HCl 50 mg diluted to 1.8 mL by distilled water (Group B)
Study: 19470838
Drug: Actovegin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (2,000 mg/day intravenous infusions for 20 days, followed by 1,800 mg/day oral tablets for 140 days)
Study: 16960547
Drug: Episodic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic therapy with valacyclovir (500 mg twice daily for 5 days)
Study: 16960547
Drug: Suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive therapy with valacyclovir (500 mg daily)
Study: 15561445
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (TN)
Study: 15007373
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (NS)
Study: 12564655
Drug: RSG+SU (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG+SU (4 mg rosiglitazone daily plus sulphonylurea)
Study: 9857665
Drug: Rifamazid (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifamazid (fixed-dose combination)
Study: 9857665
Drug: Free simultaneous
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free simultaneous combination of rifampicin and isoniazid
Study: 2083193
Drug: Diltiazem titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem titration from 240 to 360 mg/day (q12h)
Study: 2083193
Drug: Diltiazem titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem titration from 180 to 270 to 360 mg/day (q8h)
Study: 30714233
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination containing polyphenols from Ascophyllum nodosum and Fucus vesiculosus and chromium picolinate
Study: 30714233
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination
Study: 28427580
Drug: DES-PCI (Drug-Eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES-PCI (Drug-Eluting Stents)
Study: 26003637
Drug: Vasoactive drugs
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive drugs usage in group II
Study: 23455193
Drug: Innovator drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator drug (Singulair)
Study: 23455193
Drug: Locally manufactured
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Locally manufactured drug (Montiget)
Study: 15515782
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) 5 million IU administered subcutaneously
Study: 11429627
Drug: CHO (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (2.6 g kg‐1 carbohydrate)
Study: 11429627
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + CAF (2.6 g kg‐1 carbohydrate + 6 mg kg‐1 caffeine)
Study: 11429627
Drug: FAT (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAT (1.2 g kg‐1 fat with 2000 U I.V. heparin)
Study: 11429627
Drug: FAT +
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAT + CAF (1.2 g kg‐1 fat with 2000 U I.V. heparin + 6 mg kg‐1 caffeine)
Study: 9359648
Drug: Local continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local continuous (LC) injection of carboplatin (30 mg/day for 3, 7 or 14 days)
Study: 9359648
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of carboplatin (210 mg)
Study: 7923492
Drug: Internal rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal rectal procidentia rectopexy
Study: 27993104
Drug: T-2 toxin
Normalized name: T-2 toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-2 toxin at 0.15, 0.33 and 1.82 mg kg‐1 body weight
Study: 27993104
Drug: Deoxynivalenol (DON)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxynivalenol (DON) at 0.13, 0.31 and 1.75 mg kg‐1 body weight
Study: 27993104
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose of both mycotoxins
Study: 27993104
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of both mycotoxins
Study: 25046787
Drug: 2 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L/min of oxygen via nasal cannula
Study: 23462927
Drug: Caffeine-containing energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing energy drink (3 mg/kg body mass)
Study: 12854150
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg orally every day from 28 weeks of gestation until 30 days after labor)
Study: 8174495
Drug: Imipenem/cilastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (1 g q 8 h)
Study: 3580237
Drug: Midazolam given
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam given by infusion